The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biomarkers market report forecasts the biomarkers market size to grow to $104.85 Billion by 2027, with a CAGR (compound annual growth rate) of more than 14%.

Learn More On The Biomarkers Market Report 2023 – https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Biomarkers Market Size Forecast
The global biomarkers market is expected to grow from $54.4 billion in 2022 to $61.72 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biomarkers market size is expected to grow to $104.85 billion in 2027 at a CAGR of 14.2%.

North America held the largest biomarkers market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Biomarkers Market Driver ­– Increase In Heart Diseases
For instance, in March 2021, according to National Center for Health Statistics (NCHS) and National Vital Statistics System (NVSS), there has been a substantial increase in heart diseases from 2019 to 2020. Heart disease deaths increased by 4.8% in the US in 2020, the largest increase in heart disease deaths since 2012. In the US, nearly 6,908,820 people died in 2020 of heart disease. Because of the increase in heart diseases and heart deaths, there will be an increase in growth for the biomarkers.

Request for A Sample Of The Global Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

Key Biomarkers Market Trend – Rising New Agreements Between The Companies
Major companies operating in the biomarkers market are focused on making agreements with other players to develop and launch new solutions and strengthen their position. For instance, in July 2020, Thermo Fisher Scientific, a US-based analytical laboratory instrument manufacturing company signed a companion diagnostic (CDx) agreement with a Japan-based pharmaceutical company Chugai Pharmaceutical. This agreement helps to expand the use of the Oncomine Dx Target Test and expedite local biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for Rozlytrek (entrectinib) treatment in Japan. In addition, in September 2020, Thermo Fisher Scientific announced new collaborations among the Thermo Fisher Precision Medicine Science Center, AstraZeneca (a UK-based pharmaceutical and biotechnology company), and the University of Nebraska Medical Center for clinical biomarker discovery. This collaboration intends to create standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation.

Biomarkers Market Segment
1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases
3) By Type: Biomarker Of Exposure, Biomarker Of Diseases
4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies
5) By Application: Risk Assessment, Development of Molecular Diagnostic, Disease Diagnosis, Drug Discovery And Development, Drug Formulation, Forensic Application, Other Applications (DNA Fingerprinting And Others )

Biomarkers Market Major Players and Strategies
Major players in the biomarkers market are Enzo Biochem Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN, Epigenomics AG, F Hoffmann-La Roche Ltd., Abbott, Meso Scale Diagnostics LLC, EKF Diagnostics Holdings plc, GE Healthcare, Agilent Technologies Inc., Johnson & Johnson Services Inc., Siemens, and Thermo Fisher Scientific Inc.

In October 2020, Medidata, a US-based company and a subsidiary of Dassault Systèmes, offering end-to-end solutions to support clinical development process, acquired the digital biomarker business of MC10. Through this acquisition, Medidata will integrate offering that will help healthcare and medical devices companies to get better understanding of diseases, novel endpoints, and transformational therapies. MC10 is a US-based company focused on improving human health through digital solutions.

The Biomarkers Global Market Report 2023 covers regional data on biomarkers market size, biomarkers market trends and drivers, opportunities, strategies, and biomarkers market competitor analysis. The countries covered in the biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biomarkers refer to a biological molecule that is a marker for a condition, disease, or aberrant process and can be discovered in tissues, body fluids, or blood. It is used to determine how well the body responds to a disease or condition’s treatment. These biomarkers have a clinical role in narrowing or guiding treatment decisions.

View More Reports Related To The Biomarkers Market –
Renal Biomarkers Global Market Report 2023
Small Animal Imaging Global Market Report 2023
Cancer Biomarker Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: